- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07553559
Evaluering af et kunstig intelligens-baseret diagnostisk supportværktøj til ældre voksne i primærsektoren (INTERLACE)
Fremme af diagnostisk ekspertise for ældre voksne gennem kollektiv intelligens og imitationslæring
Older adults commonly experience diagnostic errors that may lead to direct harms and increased healthcare costs. Older adults are especially at risk because of higher rates of comorbidity burden, medical complexity, frailty, and cognitive impairment. An artificial intelligence (AI) clinical decision support system (CDSS) offer a promising approach to promote diagnostic excellence for older adults.
The purpose of this study is to assess the acceptability and feasibility of a new AI CDSS for older adults in primary care. The goal of this AI CDSS is to provide diagnostic support during primary care visits (i.e., help make timely and accurate diagnoses) and support communication amongst patients, doctors, and caregivers about the patient's health.
In this study, participants will use the AI CDSS in a primary care visit and review its suggestions for diagnoses and tests. Afterwards, they will complete a feedback survey and interview where they share their thoughts about and experience using the AI CDSS.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Alyssa M Sliwa, BA
- Telefonnummer: 215-746-3080
- E-mail: alyssa.sliwa@pennmedicine.upenn.edu
Undersøgelse Kontakt Backup
- Navn: Nicholas Bishop, BA
- E-mail: nicholas.bishop@pennmedicine.upenn.edu
Studiesteder
-
-
Pennsylvania
-
Philadephia, Pennsylvania, Forenede Stater, 19104
- University of Pennsylvania
-
Kontakt:
- Clinical Research Coordinator
- Telefonnummer: 215-746-3080
- E-mail: alyssa.sliwa@pennmedicine.upenn.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Clinicians
- Work in the University of Pennsylvania Health System
- Work in a primary care setting (i.e., Internal Medicine, Geriatric Medicine, Family Medicine, and Penn Primary Care)
- Actively treat adult patients who are 65 years old or older
Patients
- 65 years of age or older
- Have an upcoming encounter with a participating primary care clinician
- Indicate a new or worsening health concern that they wish to discuss at the upcoming encounter
Caregivers
- 18 years old or older
- Accompanying the participating patient during the encounter with the AI CDSS
- Identified by the patient as a caregiver
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Under the age of 18 years old
- Unable to provide informed consent in the opinion of the investigator
- Has a "Research Do Not Contact" status in the electronic health record
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Use of INTERLACE tool in primary care visit
All participants will be asked to use INTERLACE in their primary care visit. The tool will be presented on an handheld electronic device and may be used by patients, caregivers, and primary clinicians at each visit. First, the patient will input their current symptoms into INTERLACE. Then, using these symptoms, latest vital signs, and the patient's medical history, INTERLACE will make suggestions for diagnoses and tests. Patients, caregivers, and clinicians can view and discuss these suggestions together to arrive at a potential diagnosis. |
INTERLACE is an artificial intelligence-based clinical decision support tool. It uses a patient's medical history, vital signs, and current symptoms to make suggestions for diagnoses and tests. These suggestions can be considered and discussed amongst patients, caregivers, and clinicians during primary care visits to help find a good diagnosis for the patient's symptoms. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment to the end of the study interview, up to two weeks
|
Participants will complete a Feasibility of Intervention Measure (FIM) via feedback survey following the primary care visit. Responses are measured on a 5-point Likert scale. |
From enrollment to the end of the study interview, up to two weeks
|
|
Feasibility of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks
|
Feasibility will also be assessed through brief survey questions asking whether participants experienced any barriers to using INTERLACE, whether it was useful during the visit, and how long it was used (all measured on a 7-point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete the Acceptability of Intervention Measure (AIM) via feedback survey after the primary care visit. Responses to the AIM are measured on a 5-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks
|
Participants will also complete a modified version of the Technology Acceptance model (TAM). Responses to the TAM are measured on a 7-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete a Net Promoter Score assessing the likelihood that they would recommend the AI CDSS to others at the end of the survey. This will be measured on a 10-point scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Tidsramme: From enrollment until the end of the study interview, up to two weeks
|
Acceptability will also be assessed through brief survey questions assessing whether INTERLACE caused distress (measured on a 7 point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Gary E Weissman, MD, MSPH, University of Pennsylvania
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 852952
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .